sorafenib has been researched along with Macular Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alge, CS; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A | 1 |
| Collett, LC; Diago, T; Link, TP; Molina, JR; Pulido, JS; Ryan, EH | 1 |
2 other study(ies) available for sorafenib and Macular Degeneration
| Article | Year |
|---|---|
Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Light; Macular Degeneration; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Retinal Pigment Epithelium; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Therapy, Combination; Fluorescein Angiography; Humans; Macular Degeneration; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography; Ranibizumab; Recurrence; Sorafenib | 2008 |